Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.

Fitzpatrick, Rebecca; Demehri, Shadpour; Murray, Joseph; Brahmer, Julie R; Ghotbi, Elena; Barasa, Durrant; Bingham, Clifton O; Shah, Ami A et al. · J Rheumatol · 2026

Where this comes from

Record sourced from PubMed, PMID 41985925.
Also identified by DOI 10.3899/jrheum.2025-0808.C1.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

J Rheumatol 2026; doi: 10.3899/jrheum.2025-0808In the originally published online version of this article, reference 8 was missing from the list of references. The missing reference has now been added: "8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40."This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.

Read the full text

View on PubMed · Publisher (DOI)